"Medication-assisted opioid therapy includes the use of methadone or buprenorphine for the treatment of opioid addiction or dependence and the use of extended-release injectable naltrex-one (Vivitrol®) for relapse prevention in opioid addiction. Methadone is available only at the opioid treatment programs (OTPs) that are certified by SAMHSA’s Center for Substance Abuse Treatment.8 Buprenorphine may be prescribed by physicians or other authorized medical practitioners who have received Drug Addiction Treatment Act of 2000 (DATA 2000) specific training and received a waiver to prescribe the medication for treatment of opioid addiction; some of these physicians are affiliated with facilities (either OTPs or other). All physicians or approved medical personnel can prescribe injectable naltrexone.
"• The proportion of OTPs providing methadone-only treatment decreased from 60 percent of all OTP facilities in 2006 to 37 percent of all OTPs in 2016.
"• The proportion of OTPs providing methadone and buprenorphine treatment increased from 33 percent of all OTP facilities in 2006 to 47 percent in 2010 and then fell to 37 percent of all OTPs in 2016.
"• The proportion of facilities (either OTP or non-OTP) providing any buprenorphine services increased from 11 percent of all facilities in 2006 to 27 percent of all facilities in 2016.
"• The percentage of facilities providing any extended-release injectable naltrexone treatment increased from 10 to 21 percent of all facilities between 20129 and 2016."

Source

Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS): 2016. Data on Substance Abuse Treatment Facilities. BHSIS Series S-93, HHS Publication No. (SMA) 17-5039. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017, pp. 12-13.
https://www.samhsa.gov/data/s…
https://www.samhsa.gov/data/s…